ITGAV and neoplasm: These findings point to an enrichment towards the mesenchymal phenotype after tumor relapse/metastasis in cSCC patient samples, reinforcing the need for prognostic biomarkers, such as ITGAV, to detect at early stages patients at risk of developing tumor recurrences.